Vortioxetine

CAT: 0804-HY-15414-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15414-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial agonist of 5-HT1B (Ki: 15 nM, 33 nM) [1][2].
CAS Number
[508233-74-7]
Product Name Alternative
Lu AA 21004
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
5-HT Receptor; Serotonin Transporter
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Vortioxetine.html
Purity
98.61
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(C)=C1
Molecular Formula
C18H22N2S
Molecular Weight
298.45
Precautions
H302, H315, H319, H335
References & Citations
[1]Bang-Andersen B, et al. Discovery of 1-[2- (2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004) : a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54 (9) :3206-21.|[2]Guilloux JP, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 May 28;73C:147-159.|[3]Theunissen EL, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93 (6) :493-501.|[4]Rothschild AJ, et al. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22 (12) :858-66.|[5]Mrk A, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340 (3) :666-75.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
5-HT1 Receptor;5-HT3 Receptor;5-HT7 Receptor; lactoferrin; mLAG-3; MUC3
Citation 01
Antioxidants (Basel) . 2024 May 29;13 (6) :667.|Biomedicines. 2022 Jun 3;10 (6) :1318.|bioRxiv. 2024 Feb 9:2024.02.08.579543.|bioRxiv. 2025 February 08.|Eur Arch Psychiatry Clin Neurosci. 2023 Mar;77 (3) :149-159.|Eur J Pharmacol. 2025 Jul 5:998:177460.|Nature. 2023 Dec;624 (7992) :672-681.|Neurobiol Dis. 2024 Oct 1:200:106651.|Psychiat Res. November 2022, 114838.|Psychiatry Res. 2022 Nov:317:114838.|Mol Pharmacol. 2023 Nov;104 (5) :230-238.

Related Products

CatalogName

Popular Products